Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/I Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status

NCT03699319 is registered in ClinicalTrials.gov with David Bajor, MD as lead sponsor.

NCT NCT03699319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03699319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/I Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status
Lead sponsor
David Bajor, MD
Phase
Phase 1/2
Overall status
Completed
Start date
December 7, 2018
Completion date
September 23, 2024
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer